Prenumerata už 2 €

Užsitikrinkite nuo 2 eurų

Institutional-grade intelligence for professional investors

LIVE

•Real-time feeds•Global markets•24/7 coverage

Vir Biotechnology Aktie News & Pressemeldungen

Vir Biotechnology Eulerpool naujienos

2024-11-19 00:20:34

Barinthus Biotherapeutics: Fortschritte in der Hepatitis-B-Forschung mit vielversprechenden Daten

2024-12-01 18:37:24

Vir Biotechnology: Ein Blick auf den Cashburn-Radar

2025-01-09 01:00:28

Quantencomputing-Aktien unter Druck: Nvidia-Chef Jensen Huang sorgt für heftige Kursverluste

2025-01-09 16:39:50

Vir Biotechnology präsentiert vielversprechende Ergebnisse bei Krebs-Immuntherapien

2025-01-09 20:29:56

Vir Biotechnology verzeichnet kräftigen Kursanstieg dank erfolgreicher Phase-2-Studien

1

1

Vir Biotechnology akcijų naujienos

Vir Biotechnology stebi daugybė žurnalistų ir investuotojų visame pasaulyje. Naujausias Vir Biotechnology naujienas mes pateikiame čia.

liepos 31 d. ·
Yahoo
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
liepos 25 d. ·
Yahoo
First subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525
liepos 24 d. ·
Yahoo
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
liepos 23 d. ·
SeekingAlpha
Vir Biotechnology: Hep B And Cancer Projects March On
liepos 14 d. ·
Yahoo
Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board
liepos 11 d. ·
Yahoo
CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls
liepos 10 d. ·
Yahoo
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
gegužės 29 d. ·
Yahoo
Spero Therapeutics And 2 Other Promising Penny Stocks To Watch
gegužės 9 d. ·
Yahoo
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
gegužės 8 d. ·
SeekingAlpha
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

1

2

1

2

Vir Biotechnology Akcijų Pranešimai spaudai

Vir Biotechnology reguliariai skelbia pranešimus, kurie yra svarbūs investuotojams, įmonės interneto svetainėje.

Professional-grade financial intelligence

20M+ securities. Real-time data. Institutional insights.

Užtikrinkite nuo 2 eurų

Trusted by professionals at Goldman Sachs, BlackRock, and JPMorgan